Contineum Therapeutics, Inc.

Develops oral small molecule therapies for neurological, inflammatory, and fibrotic diseases.

CTNM | US

Overview

Corporate Details

ISIN(s):: US21217B1008
LEI:
Country:: United States of America
Address:: 3565 GENERAL ATOMICS COURT, SUITE 200, 92121 SAN DIEGO
Website:: https://www.contineum-tx.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Contineum Therapeutics, Inc. is a clinical-stage biopharmaceutical company that discovers and develops novel, oral small molecule therapies. The company focuses on pioneering treatments for conditions at the intersection of neuroscience, inflammation, and immunology (NI&I). Its pipeline is based on clinically validated biological targets and includes a potential best-in-class LPA1R antagonist for idiopathic pulmonary fibrosis (IPF) and progressive multiple sclerosis (PrMS), and a potential first-in-class M1R antagonist for major depressive disorder (MDD) in collaboration with a Johnson & Johnson company. Formerly Pipeline Therapeutics, Contineum aims to develop impactful treatments for serious neurological, inflammatory, and fibrotic diseases.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Contineum Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Contineum Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Contineum Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

	Company	Country	Ticker
	Lexeo Therapeutics, Inc. Develops AAV gene therapies for genetic cardiovascular and Alzheimer's diseases.	United States of America	LXEO
	LEXICON PHARMACEUTICALS, INC. Develops gene-based drugs for chronic diseases, including treatments for heart failure.	United States of America	LXRX
$LIFECORE BIOMEDICAL, INC. \DE\ Logo$	LIFECORE BIOMEDICAL, INC. \DE\ A CDMO for parenteral drugs, producing injectable-grade sodium hyaluronate (HA).	United States of America	LFCR
	Liminatus Pharma, Inc. Clinical-stage immuno-oncology firm developing cancer therapies targeting the CD47 checkpoint.	United States of America	LIMN
	Lineage Cell Therapeutics Inc. Developing off-the-shelf cell therapies for neurological and ophthalmic conditions.	Israel	LCTX
	Lineage Cell Therapeutics, Inc. Developing off-the-shelf cell therapies for neurological and ophthalmic conditions.	United States of America	LCTX
	Lipigon Pharmaceuticals AB Develops novel drugs for lipid metabolism disorders to reduce cardiovascular disease risk.	Sweden	LPGO
	Lipocine Inc. Biopharma developing oral drugs for metabolic & endocrine disorders using delivery technology.	United States of America	LPCN
	Lipum AB Develops first-in-class antibody treatments for chronic inflammatory diseases like arthritis.	Sweden	LIPUM
	Liquidia Corp Develops inhaled therapies for rare cardiopulmonary diseases using proprietary PRINT® technology.	United States of America	LQDA